Theravance Biopharma, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2013 | — | $-17.0M | $0 |
| FY2014 | — | $289.8M | $277.5M |
| FY2015 | — | $243.1M | $112.7M |
| FY2016 | — | $350.2M | $344.7M |
| FY2017 | $223.7M | $115.2M | $89.0M |
| FY2018 | $454.4M | $-51.6M | $378.0M |
| FY2019 | $455.0M | $-223.8M | $58.1M |
| FY2020 | $619.2M | $-303.8M | $81.5M |
| FY2021 | $616.3M | $-338.6M | $90.0M |
| FY2022 | — | $441.8M | $298.2M |